Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.

msh id	LIFE:ATAI
symbol	ATAI
name	Atai Life Sciences N.V.
homepage url	https://www.atai.life
country	DE
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	83
crunchbase url	-
linkedin url	-
founders	-

market cap	220.98M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-0.13
growth cost of revenue	0.9
growth depreciation and amortization	-0.55
growth ebitda	0.13
growth ebitda ratio	0.36
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-0.1
growth gross profit	-1.08
growth gross profit ratio	-1.06

LIFE:ATAI

atai Life Sciences

Last Close

1.59

21/11 21:00

Market Cap

220.98M

Beta: -

Volume Today

1.26M

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	125.78M
cost of revenue	125.78M
depreciation and amortization	319K
ebitda	-125.15M
ebitda ratio	-398.57
eps	-0.25
eps diluted	-0.25
operating expenses	125.47M
operating income	-125.47M
operating income ratio	-399.59

accounts receivables	-2.01M
capital expenditure	-590K
cash at beginning of period	190.61M
cash at end of period	45.03M
inventory	1
working capital ttm	197.65M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-